Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years—a registry-based study by the Acute Leukemia Working Party of the EBMT
暂无分享,去创建一个
J. Bourhis | M. Labopin | P. Chevallier | I. Yakoub-Agha | D. Blaise | A. Nagler | M. Mohty | F. Ciceri | G. Socié | E. Forcade | Z. Perić | M. Stelljes | A. Spyridonidis | C. Schmid | E. Brissot | K. Hirschbühl | S. Giebel | H. Labussière-Wallet | E. Polge | B. Savani | W. Bethge | Sarah Bonnet
[1] H. Nakasone,et al. Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation , 2022, International Journal of Hematology.
[2] J. Pavlů,et al. How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia , 2021, Clinical Hematology International.
[3] H. Eich,et al. The Burden of Survivorship on Hematological Patients—Long-Term Analysis of Toxicities after Total Body Irradiation and Allogeneic Stem Cell Transplantation , 2021, Cancers.
[4] L. Constine,et al. Pulmonary Toxicity After Total Body Irradiation – Critical Review of the Literature and Recommendations for Toxicity Reporting , 2021, Frontiers in Oncology.
[5] Maria Vittoria Dubbini,et al. Conditioning Regimens for Frail Patients with Acute Leukemia Undergoing Allogeneic Stem Cell Transplant: How to Strike Gently , 2021, Clinical hematology international.
[6] J. Pidala,et al. Impact of total body irradiation based myeloablative conditioning regimen in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant: systematic review and meta-analysis. , 2021, Transplantation and cellular therapy.
[7] N. Kröger,et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years , 2021, Bone Marrow Transplantation.
[8] J. Esteve,et al. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the , 2021, Leukemia.
[9] H. Tilly,et al. Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party , 2020, Bone Marrow Transplantation.
[10] A. Ganser,et al. Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT , 2020, Bone Marrow Transplantation.
[11] I. Kabbash,et al. Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation , 2020, Journal of the Egyptian National Cancer Institute.
[12] J. Lee,et al. Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia , 2020, Yonsei medical journal.
[13] S. Kako,et al. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT , 2020, Bone Marrow Transplantation.
[14] M. Labopin,et al. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation—a retrospective study by the Acute Leukemia Working Party of EBMT , 2020, Bone Marrow Transplantation.
[15] N. Kröger,et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT , 2019, Journal of Hematology & Oncology.
[16] J. Esteve,et al. Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) , 2019, Annals of Hematology.
[17] H. Garelius,et al. Survival in adult acute lymphoblastic leukaemia (ALL): A report from the Swedish ALL Registry , 2019, European journal of haematology.
[18] K. Dusenbery,et al. Influence of Total Body Irradiation Dose Rate on Idiopathic Pneumonia Syndrome in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. , 2019, International journal of radiation oncology, biology, physics.
[19] B. Hayes-Lattin,et al. Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward , 2018, Current Hematologic Malignancy Reports.
[20] M. Labopin,et al. Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph‐negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation , 2018, American journal of hematology.
[21] M. Labopin,et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT , 2017, Oncotarget.
[22] B. Sandmaier,et al. Reduced intensity conditioned allograft yields favorable survival for older adults with B‐cell acute lymphoblastic leukemia , 2017, American journal of hematology.
[23] J. Radich,et al. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. , 2016, Blood advances.
[24] R. Foà,et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study , 2016, Haematologica.
[25] J. Esteve,et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpl , 2016, Cancer.
[26] P. Sonneveld,et al. Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival , 2016, Leukemia.
[27] Jinny Park,et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. , 2015, Blood.
[28] H. Greinix,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .
[29] B. Cho,et al. Comparable long‐term outcomes after reduced‐intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high‐risk acute lymphoblastic leukemia in complete remission , 2013, American journal of hematology.
[30] M. Maris,et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia , 2011, Haematologica.
[31] D. Porter,et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2011, Blood.
[32] J. Esteve,et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. , 2010, Blood.
[33] S. Riddell,et al. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[34] Mei-Jie Zhang,et al. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[35] Daniel Wolff,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[36] T. Yamane,et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients , 2005, Bone Marrow Transplantation.